1. Updated Contact Information
- The CBER contact method changed from the general "Office of Communication, Outreach and Development" (phone/email) to a specific email address, industry.biologics@fda.hhs.gov, alongside the same phone number.
2. Framing of the Guidance's Purpose
- The draft's introduction talks about improving the "diversity of clinical trial populations."
- The final version replaces this with improving the "applicability of clinical trial data to U.S. populations." This is a meaningful shift in emphasis — away from "diversity" language toward broader applicability/generalizability language. Correspondingly, the footnote citing FDA's separate "Enhancing the Diversity of Clinical Trial Populations" guidance is dropped in the final version.
- The final version adds a new clarifying line noting that many of the concepts in the guidance may apply more broadly to other clinical areas, not just oncology.
- Terminology throughout shifts from "trial participants" (draft) to "trial subjects" (final).
3. Related Guidance List Expanded
- The footnote listing companion guidances in this series now includes two newly issued documents: Lab Values (July 2026) and Performance Status (July 2026). Industry should be aware there are now related guidances covering these adjacent eligibility topics.
4. Concomitant Medications — Scope Narrowed on Dietary Supplements
- The draft's definition of "concomitant medications" explicitly included "over-the-counter drugs and dietary supplements."
- The final guidance removes dietary supplements from the core definition, defining concomitant medications as prescription and over-the-counter drugs only. It adds a separate sentence acknowledging that although the guidance is focused on concomitant medications, products such as dietary supplements that aren't regulated as drugs or biologics may still interfere with drug clearance — treating them as a distinct, secondary consideration rather than as part of the primary concomitant medication framework.
5. Language on Washout Period Rationale Broadened
- The final version adds an additional justification for washout periods: preventing prior therapy from interfering with the pharmacokinetics/pharmacodynamics (PK/PD) of the investigational drug — not just preventing additional toxicity, as in the draft.
6. Reordering and Emphasis in Washout Period Recommendations
- In the draft, the bullet on time-based washout periods is listed first, followed by the bullet on using clinical/laboratory parameters instead.
- In the final version, this order is reversed: the recommendation to use clinical and laboratory parameters in place of time-based washout periods now comes first, ahead of the discussion of time-based washouts. This subtle resequencing signals FDA's continued preference for lab/clinical-parameter-based criteria over fixed time-based washout windows.
7. Concomitant Medications Recommendations — Consolidated and Reframed
- The draft has three separate bullets: (1) excluding patients only for clinically relevant drug-drug interactions/overlapping toxicity, (2) noting that concomitant medication use may require modifying the investigational drug's dosage/regimen, and (3) noting that concomitant medication dosages may themselves need modification, with patients/caregivers informed of changes.
- The final version consolidates bullets (2) and (3) into a single bullet, framed explicitly as an alternative to excluding patients: sponsors "may also consider modification of the dosage or regimen of the investigational anti-cancer agent or the concomitant medications," with the same requirement that this be justified, specified in the protocol, and communicated to patients/caregivers. This reframes dose modification as a stated alternative pathway to exclusion, rather than two separate, freestanding considerations.
8. Sponsor Discretion Language Softened
- The draft states sponsors "can also provide alternatives to prohibited concomitant medications in trial protocols."
- The final version tempers this to sponsors "may, if applicable, provide alternatives" — slightly softer, conditional phrasing.
9. Illustrative Example Made More Explicit
- Both versions caution against vague exclusion language (e.g., "Exclude patients taking a concomitant medication expected to increase the risk for a clinically significant adverse event"), but the final version explicitly frames this as an example to avoid ("For example, sponsors should avoid statements such as..."), making the instructional intent clearer.
The differences are generated by AI models and can contain mistakes. Please double-check the content.